Symposia Replay Hub
Access recordings from Idorsia-sponsored symposia featuring healthcare professionals discussing clinical data and practical considerations for QUVIVIQ™▼ (daridorexant) in chronic insomnia.
Clinical Pharmacy Congress 2025:
Sponsored Symposium Highlight
Hear from John Donoghue, mental health pharmacist, as he discusses the management of chronic insomnia. This session covers:
- Medication options for insomnia management
- The role of orexin in the sleep-wake cycle
- Clinical evidence for daridorexant from phase 3 trials
- NICE TA922 guidance on treatment of chronic insomnia
- Practical considerations for dual orexin receptor antagonists (DORAs)
Chapters
- Introduction to chronic insomnia & associated implications [00:00 – 04:53]
- NICE Clinical Knowledge Summary (CKS) – Recommendations for long-term insomnia [04:54 – 06:56]
- Medicines used to treat insomnia – Benzodiazepines & Z-drugs [06:57 – 11:43]
- Medicines used to treat insomnia – Melatonin [11:44 – 14:35]
- Medicines used to treat insomnia – Introduction to orexin & the sleep/wake cycle [14:36 – 18:48]
- QUVIVIQ™ (daridorexant): A dual orexin receptor antagonist – Clinical trials overview [18:49 – 33:29]
- Subjective outcomes & patient-reported outcomes
- Side effects
- Long-term data (12-month study)
- NICE technology appraisal (TA): QUVIVIQ™ (daridorexant) for treating long-term insomnia (TA922) [33:30 – 37:03 (end)]
If you want to see the chapters directly on the video, click on the icon in the video player:
Speaker
RCGP recording - Placeholder
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Speaker
Dr XX XXXXX
Gain access to resources on chronic insomnia
Subscribe to get priority updates and access to videos, data and patient resources, plus details about us and our offerings.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
Works differently1,2
Is taken differently1,3
Is experienced differently1,4
Book an appointment
One of our product specialists would be happy to answer your questions.
QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed November 2025.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
